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and men with diabetes-related comorbidities/complications by
13% and 5% compared to IDDM without diabetes reated
comorbidities/complications. The probability of working for
women and men with NIDDM also were 7% and 2% less than
women and men without this disorder. Similarly, these proba-
bilities were even smaller for women and men with NIDDM
related comorbidities/complications by 2% compared with
NIDDM without diabetes reated comorbidities/complications
(all at p-values <0.05). The predicted weekly work hours for
women and men without diabetes were 29 and 41 hours, with
IDDM were 18 and 30, with IDDM and comorbidities/compli-
cations were 13 and 23, with NIDDM were 21 and 35 hours
and ﬁnally with NIDDM and related comorbidities/complica-
tions were 17 and 30, respectively. CONCLUSIONS: The effect
of diabetes and its related comorbidities especially for men with
NIDDM and related comorbidities/complications on the proba-
bility of unemployment and predicted weekly work hours in
Canada are substantial. The results of this study have implica-
tions for cost-effectiveness of diabetes control and may facilitate
studies of the health burden of diabetes for the prevention and
treatment of diabetes and thus increase the labor productivity.
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OBJECTIVES: A 24-month randomised, open-label parallel
group study in type 2 diabetes patients compared the safety and
efﬁcacy of biphasic insulin aspart (BIAsp30/70) and biphasic
human insulin (BHI30/70) injected twice daily before meals.
Major hypoglycaemic episodes were reduced with BIAsp30/70
(annual rate 4.1%) versus BHI30/70 (annual rate 15.5%) and
were signiﬁcantly lower in the second study year (p = 0.04). Gly-
caemic control did not differ between groups. A peer-reviewed,
validated model projected the impact of the different rates of
major hypoglycaemia events on long-term health economic out-
comes in multinational settings. METHODS: The CORE Dia-
betes model employs standard Markov/Monte Carlo simulation
techniques to describe long-term incidence and progression of
diabetes-related complications. Transition probabilities were
derived from major diabetes studies. The clinical effects of the
comparators were derived from the trial described. The analysis
was performed in multinational settings using published country-
speciﬁc costs, health care resource utilization, clinical data, and
recommended discount rates. A lifetime horizon and payer per-
spective was taken. Only direct costs were considered. Sensitiv-
ity analyses was performed. RESULTS: Discounted
quality-adjusted life years (QALY) were improved by 0.15–0.22
years with BIAsp30/70 versus BHI30/70 depending on country
speciﬁc discount rates. Increases in lifetime costs were seen with
BIAsp30/70 in all settings. Costs per QALY were DKK61,922,
9784€, 12,840€, NOK38,911€, 14,068€, SEK76,495€, and
£6,585 in the Danish, Finnish, German, Norwegian, Spanish,
Swedish, and UK setting respectively. Results were most sensi-
tive to assumptions regarding major hypoglycaemia rates, mor-
tality following major hypoglycemic events, HbA1c changes and
to the relative costs of BIAsp30/70 versus BHI30/70. CON-
CLUSIONS: Treatment with BIAsp30/70 was projected to result
in additional QALYS and reduced health care costs associated
with major hypoglycaemic events versus treatment with
BHI30/70. The higher acquisition costs of BIAsp30/70 led to
increased overall costs, but the incremental cost/QALY fell
within the range generally considered to be cost-effective in each
country.
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OBJECTIVE: We report on the results of proof-of-concept study
designed to encourage patient adherence to treatment guidelines
and allow German physicians treating patients with Type-2 dia-
betes with nateglinide to gain patient feedback using an entirely
wireless design. Subject Sample: 60 patients and 5 physicians
agreed to participate in the study. METHODS: Using mobile
communications devices, patients reported on their medication-
taking experience and clinical values, including blood glucose
levels, according to a clinical protocol have ﬁve (5) patient
reporting events during the study period of 14 days. This infor-
mation was then delivered via dedicated web technology to treat-
ing physicians. RESULTS: Participating physicians enrolled an
average of seven patients in the study. Each physician visited the
website an average of 40 times. Twenty-one percent of these
visits involved the physician reviewing individual patient
responses. Sixty percent of physicians agreed that their under-
standing of the medication and of the condition was improved
by their participation in the study. Sixty-ﬁve percent of patients
reported believing that the wireless handset device was easy to
use, and 71% noted that the screen of the device was acceptable
for reading, navigating and entering information about their con-
dition. CONCLUSIONS: In a small, proof-of-concept study
designed to assess the viability of entirely automated communi-
cations among physicians and patients regarding treatment and
clinical endpoints in Type-2 diabetes, both physicians and
patients were able to use the system without signiﬁcant difﬁculty
and reported favorable experiences with the approach.
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OBJECTIVES: The aim of this study was to project the long term
costs and outcomes of continuous subcutaneous insulin infusion
(CSII) compared with multiple daily injection (MDI) in patients
with type 1 diabetes (T1D) in the UK. METHODS: The CORE
Diabetes Model is a peer-reviewed, validated model that employs
standard Markov/Monte Carlo simulation techniques to describe
the long term incidence and progression of diabetes-related com-
plications. Baseline cohort characteristics were taken from pub-
lished studies of T1D in the UK (mean age 26 years, duration of
diabetes 12 years, 54% male, 90% Caucasian, mean HbA1c
8.68%). Transition probabilities were derived from major dia-
betes clinical studies. Effects associated with CSII and MDI deliv-
